Quest Diagnostics/$DGX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Quest Diagnostics
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
- Ticker
- $DGX
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 51,500
- Headquarters
- Secaucus, United States
- Website
- www.questdiagnostics.com
DGX Metrics
BasicAdvanced
$28B
25.09
$10.04
0.54
$3.38
1.37%
Price and volume
Market cap
$28B
Beta
0.54
52-week high
$256.99
52-week low
$171.18
Average daily volume
1.1M
Dividend rate
$3.38
Financial strength
Current ratio
1.7
Quick ratio
1.368
Long term debt to equity
0.773
Total debt to equity
0.783
Dividend payout ratio (TTM)
32.68%
Interest coverage (TTM)
6.62%
Profitability
EBITDA (TTM)
2,352
Gross margin (TTM)
33.18%
Net profit margin (TTM)
9.53%
Operating margin (TTM)
14.75%
Effective tax rate (TTM)
22.47%
Revenue per employee (TTM)
$230,000
Management effectiveness
Return on assets (TTM)
6.53%
Return on equity (TTM)
15.32%
Valuation
Price to earnings (TTM)
25.089
Price to revenue (TTM)
2.329
Price to book
3.63
Price to tangible book (TTM)
-8.9
Price to free cash flow (TTM)
20.054
Free cash flow yield (TTM)
4.99%
Free cash flow per share (TTM)
12.557
Dividend yield (TTM)
1.34%
Forward dividend yield
1.37%
Growth
Revenue change (TTM)
9.13%
Earnings per share change (TTM)
17.88%
3-year revenue growth (CAGR)
8.40%
10-year revenue growth (CAGR)
4.67%
3-year earnings per share growth (CAGR)
14.62%
10-year earnings per share growth (CAGR)
7.86%
3-year dividend per share growth (CAGR)
6.60%
10-year dividend per share growth (CAGR)
7.90%
What the Analysts think about DGX
Analyst ratings (Buy, Hold, Sell) for Quest Diagnostics stock.
Analyst projections of the future price of Quest Diagnostics stock.
Bulls say / Bears say
Quest’s operating momentum is strong: second-quarter revenue rose 10.2% and adjusted EPS rose 19.1%, prompting it to raise its 2026 revenue and EPS outlook again. That gives investors evidence of growth translating into earnings, not just higher testing volumes. (Quest Diagnostics)
Quest is extending its reach through hospital and dialysis partnerships, while its consumer testing business is growing quickly. Management said consumer revenue was growing by about 30% year on year and saw room for continued expansion, adding growth channels beyond routine physician-ordered tests. (StockAnalysis)
Quest says it is gaining share through expanded payer access and by winning work redirected from higher-cost hospital labs. Those gains, alongside acquired physician-outreach businesses, could provide further volume growth as the company uses its national network and scale. (StockAnalysis)
A coming Medicare laboratory fee reset could pressure earnings: without further legislative action, scheduled cuts of up to 15% per year are due to begin in 2027. The final rates and any congressional intervention remain uncertain, but the risk extends beyond this year’s outlook. (MedTech Dive, Quest Diagnostics)
Recent partnership volumes carry weaker revenue per test and are weighing on margins. In the second quarter, revenue per requisition fell 2.8% and adjusted operating margin slipped to 16.5% from 16.9% a year earlier. (Quest Diagnostics)
Higher compensation costs are absorbing part of the benefit from rising test volumes and productivity savings. Quest’s filing says these costs drove most of the increase in service costs in the first half, leaving the company reliant on efficiency programmes to counter labour and other inflationary pressures. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
DGX Financial Performance
Revenues and expenses
DGX Earnings Performance
Company profitability
Upcoming events
No upcoming events
DGX News
AllArticlesVideos
PRIVACY ALERT: AWKO Law LLP Investigates Quest Diagnostics for Data Breach of Patient Records
Business Wire1 week ago
Lab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach
TechCrunch2 weeks ago
What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call
MarketBeat2 weeks ago
Funds containing DGX
AllUSDEURGBP
Fund name | Fund size | $DGX weighting |
|---|---|---|
Invesco S&P 500 Low Volatility£SPLG | $143M | 0.89% |
SPDR S&P 500 Low Volatility$LOWV | $113M | 0.89% |
SPDR S&P 500 Low Volatility£USLV | $113M | 0.89% |
iShares Ageing Population£AGES | $953M | 0.60% |
iShares Ageing Population$AGED | $953M | 0.60% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.